3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Polycythemia Vera
1
Peritoneal Neoplasms
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Interventions
Paclitaxel
24
Hyperthermic Intraperitoneal Chemotherapy
24
Cisplatin
22
Oxaliplatin
17
Carboplatin
17
Fluorouracil
13
Cytoreduction Surgical Procedures
13
Bevacizumab
10
Mitomycin
9
Leucovorin
8
Doxorubicin
8
Docetaxel
6
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
Surgical Procedures, Operative
4
Blood Specimen Collection
4
Albumin-Bound Paclitaxel
4
sodium thiosulfate
3
liposomal doxorubicin
3
catumaxomab
3
Taxes
3
Neoadjuvant Therapy
3
Laparoscopy
3
Drug Therapy
3
tremelimumab
2
relacorilant
2
pembrolizumab
2
olaparib
2
nintedanib
2
epothilone B
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Peritoneal Neoplasms
×
Hypericum extract LI 160
×
Clear all
NCT02840331
2017-10-27
Hypericin-PDT
University Hospital Tuebingen
Phase 3
Unknown
50 enrolled